NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AltPep

AltPep

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://altpep.com/

Last Round

Series B

Jun 22, 2023

Total Funding Raised

$120.45M

Company Overview

AltPep is a biotechnology company that operates a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors to amyloid diseases, offering innovative solutions for early detection and treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

Alzheimer's diseasepeptide therapeuticsneurodegenerative diseaseamyloid-betabiotechdrug discoveryearly-stage detectionamyloid oligomerspreclinical developmentdiagnostic assayneuroscienceclinical trialsprotein misfoldingbiopharmatherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AltPep Comps

Public and private peers based on sector, stage, and business model.

AltPep comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AltPep Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 22, 2023
Series BJul 26, 2022
Series AJan 14, 2021

Key People

Founding team and executive leadership

Valerie Daggett

Founder And CEO

Founding Team

Nancy Hill

Chief Product Officer

Executive Team

AltPep Investors

Notable investors and investment history

AltPep investors
InvestorRounds
S32Series B
Senator Investment GroupSeries B
Alexandria Venture InvestmentsSeries B, Series A
Matrix Capital ManagementSeries B, Series A
Partners InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2025

    New preclinical data for SOBIN-AD showed improved behavior in disease models.

  • Dec 1, 2025

    Presented at the CTAD 2025 conference on December 1, 2025.

AltPep Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AltPep Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AltPep's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range33
Year Founded2018
Last FundingJun 22, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.